March 2, 2026 at 2pm ET
Join the experts from Wakely, an HMA Company, for a data-driven discussion of the key Part D benefit trends shaping Medicare Advantage Part D plans in CY2026. The Inflation Reduction Act’s Part D benefit redesign commenced January 1, 2025, with Maximum Fair Price drugs introduced January 1, 2026. As benefit design becomes more uniform across Part D plans, this webinar explores how sponsors adjusted the Part D benefits of their plans to meet the requirements of the legislation, while still remaining competitive. We will review the CY2025->CY2026 movements of Part D benefits and formulary placement, in addition to exploring benefit & formulary differences between MAPD & PDP plans for CY2026.
Learning Objectives:
-Understand the benefit changes Part D sponsors applied for CY2026.
-Explore changes in formulary tier placement of drugs for CY2026.
-Compare and contrast MAPD versus PDP formulary & benefit decisions for CY2026.
